 |
|
|
|
 |
|
|
| Article 1 to 10 out of 12 concerning Bayer AG
|
-
Bayer Reports Progress in Clinical Program for Riociguat - Novel approach for the treatment of pulmonary hypertension
(07 Oct 2008)
Positive Phase II Findings Reported at European Respiratory Society Meeting / Phase III Studies to Begin in 2008
Based on positive Phase II trial findings, Bayer Schering Pharma will move into Phase III trials with its oral agent riociguat (BAY 63-2521). Riociguat is the first member of a new class of vasodilating agents called soluble guanylate cyclase (sGC) ...
-
Bayer’s Novel Anticoagulant Xarelto now also Approved in the EU
(02 Oct 2008)
Bayer will start marketing the new oral, once-daily anticoagulant very soon / First-in-class product to demonstrate superior efficacy to current standard of care
The Bayer Group has achieved a major success in its product development: The European Commission has granted marketing approval for Xarelto® (rivaroxaban), a novel anticoagulant taken as one tablet, once-daily, for the prevention of venous blood ...
-
Pilot plant for future-oriented technology opens in Halle: Bayer will use tobacco plants to produce medicines
(18 Jun 2008)
First development candidate from the new plant for cancer indication non-Hodgkin's lymphoma
Medicinal products from plants or even tobacco for health - a vision that could soon become reality. Bayer and its subsidiary Icon Genetics have together developed a new production process that can be used to produce biotech drugs in tobacco plants. ...
-
Bayer HealthCare: positive phase 2 results for the VEGF Trap-Eye
(02 Oct 2007)
Bayer HealthCare and development partner Regeneron Pharmaceuticals, Inc. announced positive results from a Phase 2 study evaluating the VEGF Trap-Eye in the neovascular form of age-related macular degeneration (wet AMD), one of the leading causes of ...
-
Bayer: FDA Approves Expanded Labeling for Campath to Include First-line Treatment for Leading Form of Adult Leukemia
(24 Sep 2007)
Study data demonstrated improved progression-free survival with Campath
Bayer Schering Pharma AG and Genzyme Corp. announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for Campath® (alemtuzumab) and granted regular approval for single-agent Campath ...
-
Bayer Reports Findings of Trasylol Independent Investigation
(21 Aug 2007)
Company outlines corrective actions it has undertaken
Bayer HealthCare reported findings of Mr. William Taylor's independent investigation on the i3 Drug Safety observational study on Trasylol® (aprotinin injection) to the U.S. Food and Drug Administration (FDA) and other relevant regulatory ...
-
Prophylactic Use of Recombinant Factor VIII Prevents Joint Disease in Young Boys with Hemophilia A
(13 Aug 2007)
Prophylactic infusions of recombinant factor VIII (rFVIII) significantly reduce the risk of developing joint damage associated with joint bleeding in young children with hemophilia A, according to a new landmark study published today in the New ...
-
Bayer CropScience and Evogene to Collaborate on Crop Yield Improvement
(20 Jun 2007)
Evogene Ltd. and Bayer CropScience announced a collaboration to increase the productivity and yield of a Bayer CropScience core crop, especially with regard to stress conditions such as drought. Under a recently signed agreement, Bayer CropScience ...
-
Crucell announces European protein distribution deal with Talecris Biotherapeutics
(04 Apr 2007)
Crucell N.V. announced a long-term distribution deal with North Carolina-headquartered Talecris Biotherapeutics, GmBH. Under the terms of the agreement, Crucell will serve as the exclusive distributor of Talecris' Prolastin® (alpha-1 proteinase ...
-
Bayer and Ortho-McNeil, Inc. Outline Phase III Study Program of Oral Factor Xa Inhibitor Rivaroxaban in Chronic Indications
(10 Nov 2006)
Patient Recruitment for Phase III Clinical Trial to Start in Studies of Oral Anticoagulant in Chronic Indications
After extensive discussions with the regulatory authorities in the U.S. and Europe, Bayer and Ortho-McNeil, Inc. have determined the final design of the phase III study program for the oral anticoagulant rivaroxaban in two chronic indications: ...
|
|
|
|
|
Top
